Review



ctr1 sirna si ctr1  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology ctr1 sirna si ctr1
    High expressions of <t>Ctr1</t> mRNA and protein in ESCC tissues and cells. A: Representative image of Ctr1 high expression in ESCC tissues by ISH and IHC; ISH and IHC assay for Ctr1 mRNA and protein expressions in 108 cases of ESCC tissues and paired normal esophageal epithelial tissues, Bar=100 μm. B: Semi-quantitative RT-PCR detection for Ctr1 mRNA expression in randomly selected 10 cases of ESCC tissues and paired normal tissues using Ctr1 specific primers. C: Statistical assay for Ctr1 relative level in ESCC tissues and paired normal tissues, * P <0.05, ** P <0.01, *** P <0.001 and **** P <0.0001, compared para-carcinoma tissues. D: qRT-PCR assay for Ctr1 mRNA expression in ESCC cell lines (Kyse70, Eca109, and Kyse450 cells), ** P <0.01 and *** P <0.001, compared with Het-1A cell. E: Western blot analysis for Ctr1 protein expression in ESCC cell lines (Kyse70, Eca109, and Kyse450 cells), and β-actin was used as loading control. F: Relative Ctr1 protein level in various ESCC cell lines (Kyse70, Eca109, and Kyse450 cells), ** P <0.01, compared with Het-1A cell.
    Ctr1 Sirna Si Ctr1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctr1+sirna+si+ctr1/CTR1+siRNA/pmc09876974-69-7-10
    Average 94 stars, based on 3 article reviews
    ctr1 sirna si ctr1 - by Bioz Stars, 2026-10
    94/100 stars

    Images

    1) Product Images from "Copper transporter Ctr1 contributes to enhancement of the sensitivity of cisplatin in esophageal squamous cell carcinoma"

    Article Title: Copper transporter Ctr1 contributes to enhancement of the sensitivity of cisplatin in esophageal squamous cell carcinoma

    Journal: Translational Oncology

    doi: 10.1016/j.tranon.2023.101626

    High expressions of Ctr1 mRNA and protein in ESCC tissues and cells. A: Representative image of Ctr1 high expression in ESCC tissues by ISH and IHC; ISH and IHC assay for Ctr1 mRNA and protein expressions in 108 cases of ESCC tissues and paired normal esophageal epithelial tissues, Bar=100 μm. B: Semi-quantitative RT-PCR detection for Ctr1 mRNA expression in randomly selected 10 cases of ESCC tissues and paired normal tissues using Ctr1 specific primers. C: Statistical assay for Ctr1 relative level in ESCC tissues and paired normal tissues, * P <0.05, ** P <0.01, *** P <0.001 and **** P <0.0001, compared para-carcinoma tissues. D: qRT-PCR assay for Ctr1 mRNA expression in ESCC cell lines (Kyse70, Eca109, and Kyse450 cells), ** P <0.01 and *** P <0.001, compared with Het-1A cell. E: Western blot analysis for Ctr1 protein expression in ESCC cell lines (Kyse70, Eca109, and Kyse450 cells), and β-actin was used as loading control. F: Relative Ctr1 protein level in various ESCC cell lines (Kyse70, Eca109, and Kyse450 cells), ** P <0.01, compared with Het-1A cell.
    Figure Legend Snippet: High expressions of Ctr1 mRNA and protein in ESCC tissues and cells. A: Representative image of Ctr1 high expression in ESCC tissues by ISH and IHC; ISH and IHC assay for Ctr1 mRNA and protein expressions in 108 cases of ESCC tissues and paired normal esophageal epithelial tissues, Bar=100 μm. B: Semi-quantitative RT-PCR detection for Ctr1 mRNA expression in randomly selected 10 cases of ESCC tissues and paired normal tissues using Ctr1 specific primers. C: Statistical assay for Ctr1 relative level in ESCC tissues and paired normal tissues, * P <0.05, ** P <0.01, *** P <0.001 and **** P <0.0001, compared para-carcinoma tissues. D: qRT-PCR assay for Ctr1 mRNA expression in ESCC cell lines (Kyse70, Eca109, and Kyse450 cells), ** P <0.01 and *** P <0.001, compared with Het-1A cell. E: Western blot analysis for Ctr1 protein expression in ESCC cell lines (Kyse70, Eca109, and Kyse450 cells), and β-actin was used as loading control. F: Relative Ctr1 protein level in various ESCC cell lines (Kyse70, Eca109, and Kyse450 cells), ** P <0.01, compared with Het-1A cell.

    Techniques Used: Expressing, Quantitative RT-PCR, Western Blot, Control

    The expressions of Ctr1 mRNA and protein in ESCC tissues and normal tissues.
    Figure Legend Snippet: The expressions of Ctr1 mRNA and protein in ESCC tissues and normal tissues.

    Techniques Used:

    The associations of Ctr1 mRNA and protein expressions with clinicopathological features in ESCC.
    Figure Legend Snippet: The associations of Ctr1 mRNA and protein expressions with clinicopathological features in ESCC.

    Techniques Used:

    The Ctr1 downregulation reduces the sensitivity of cisplatin in ESCC cells. A: Ctr1 siRNA significantly suppressed Ctr1 mRNA expression at 24 h, 48 h and 72 h in various ESCC cells (Eca109, Kyse70 and Kyse450), si-Con and si-Ctr1 were transfected to Eca109, Kyse70 and Kyse450 cells by Lipofectamine™ 2000, and Semi-quantitative RT-PCR was used to determine the relative level of Ctr1 at 24 h, 48 h and 72 h after transfection, ** P <0.01 and *** P <0.001, compared with control group and si-Con group. B: Western blot was performed to investigate the Ctr1 protein expression at 24 h, 48 h and 72 h after transfection with si-Ctr1 and si-Con in different ESCC cells (Eca109, Kyse70 and Kyse450), and β-actin was employed as a loading control. C: The relative level of Ctr1 was counted using the rate of Ctr1 protein level to β-actin level in diverse ESCC cells (Eca109, Kyse70 and Kyse450), * P <0.05, ** P <0.01 and *** P <0.001, compared with control group and si-Con group. D: The Ctr1 downregulation reduced the cytotoxicity of cisplatin in distinct ESCC cells. ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and CCK-8 was used to determine cell viability, * P <0.05, ** P <0.01, *** P <0.001 and **** P <0.0001, indicating statistical significance, compared with si-Con.
    Figure Legend Snippet: The Ctr1 downregulation reduces the sensitivity of cisplatin in ESCC cells. A: Ctr1 siRNA significantly suppressed Ctr1 mRNA expression at 24 h, 48 h and 72 h in various ESCC cells (Eca109, Kyse70 and Kyse450), si-Con and si-Ctr1 were transfected to Eca109, Kyse70 and Kyse450 cells by Lipofectamine™ 2000, and Semi-quantitative RT-PCR was used to determine the relative level of Ctr1 at 24 h, 48 h and 72 h after transfection, ** P <0.01 and *** P <0.001, compared with control group and si-Con group. B: Western blot was performed to investigate the Ctr1 protein expression at 24 h, 48 h and 72 h after transfection with si-Ctr1 and si-Con in different ESCC cells (Eca109, Kyse70 and Kyse450), and β-actin was employed as a loading control. C: The relative level of Ctr1 was counted using the rate of Ctr1 protein level to β-actin level in diverse ESCC cells (Eca109, Kyse70 and Kyse450), * P <0.05, ** P <0.01 and *** P <0.001, compared with control group and si-Con group. D: The Ctr1 downregulation reduced the cytotoxicity of cisplatin in distinct ESCC cells. ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and CCK-8 was used to determine cell viability, * P <0.05, ** P <0.01, *** P <0.001 and **** P <0.0001, indicating statistical significance, compared with si-Con.

    Techniques Used: Expressing, Transfection, Quantitative RT-PCR, Control, Western Blot, CCK-8 Assay

    Ctr1 depletion prominently repressed cell apoptosis evoked by cisplatin in ESCC cells. A: Flow cytometry assay for cell apoptosis in different ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 as well as si-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Flow cytometry was employed to determine cell apoptosis. B: Statistical assay for apoptotic cell numbers in different ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 as well as si-Ctr1 plus cisplatin, *** P <0.001 and **** P <0.0001, compared with si-Con plus cisplatin group. C: Ctr1 depletion combined cisplatin significantly suppressed the activity of Caspase-3 induced by cisplatin plus si-Con; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Caspase-3 activity kit was utilized to determine the activity of Caspase-3, *** P <0.001, compared with si-Con plus cisplatin group.
    Figure Legend Snippet: Ctr1 depletion prominently repressed cell apoptosis evoked by cisplatin in ESCC cells. A: Flow cytometry assay for cell apoptosis in different ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 as well as si-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Flow cytometry was employed to determine cell apoptosis. B: Statistical assay for apoptotic cell numbers in different ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 as well as si-Ctr1 plus cisplatin, *** P <0.001 and **** P <0.0001, compared with si-Con plus cisplatin group. C: Ctr1 depletion combined cisplatin significantly suppressed the activity of Caspase-3 induced by cisplatin plus si-Con; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Caspase-3 activity kit was utilized to determine the activity of Caspase-3, *** P <0.001, compared with si-Con plus cisplatin group.

    Techniques Used: Flow Cytometry, Transfection, Activity Assay

    The Ctr1 downregulation meliorated cell migration and invasion abilities inhibited by cisplatin in number of ESCC cells. A: Transwell assay for cell migration in various ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 and si-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Transwell chamber without Matrigel was employed to determine cell migration. B: Statistical assay for migratory cell numbers in different ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 and si-Ctr1 plus cisplatin, *** P <0.001, compared with si-Con plus cisplatin group. C: Transwell assay for cell invasion in varied ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 and si-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Transwell chamber with Matrigel was used to determine cell invasion. D: Statistical assay for invasive cell numbers in a variety of ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 and si-Ctr1 plus cisplatin, *** P <0.001, compared with si-Con plus cisplatin group.
    Figure Legend Snippet: The Ctr1 downregulation meliorated cell migration and invasion abilities inhibited by cisplatin in number of ESCC cells. A: Transwell assay for cell migration in various ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 and si-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Transwell chamber without Matrigel was employed to determine cell migration. B: Statistical assay for migratory cell numbers in different ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 and si-Ctr1 plus cisplatin, *** P <0.001, compared with si-Con plus cisplatin group. C: Transwell assay for cell invasion in varied ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 and si-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Transwell chamber with Matrigel was used to determine cell invasion. D: Statistical assay for invasive cell numbers in a variety of ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 and si-Ctr1 plus cisplatin, *** P <0.001, compared with si-Con plus cisplatin group.

    Techniques Used: Migration, Transwell Assay, Transfection

    The Ctr1 upregulation potentiated the killing efficacy of cisplatin in ESCC cells. A: pcDNA3.1-Ctr1 remarkablely enhanced the Ctr1 mRNA level at 48 h in various ESCC cells (Eca109, Kyse70 and Kyse450), pcDNA3.1 and pcDNA3.1-Ctr1 were transfected to Eca109, Kyse70 and Kyse450 cells by Lipofectamine™ 2000, and Semi-quantitative RT-PCR was used to determine the relative level of Ctr1 at 48 h after transfection,** P <0.01 and *** P <0.001, compared with control group and pcDNA3.1 group. B: Western blot was performed to investigate the Ctr1 protein expression in a number of ESCC cells 48 h after transfection with pcDNA3.1 and pcDNA3.1-Ctr1, and β-actin was used as a loading control. C: The relative level of Ctr1 protein in untreated ESCC cells, ESCC cells transfected with pcDNA3.1 and pcDNA3.1-Ctr1, ** P <0.01, compared with control group and pcDNA3.1 group. D: CCK-8 was used to examine the cell proliferative ability in different concentration of cisplatin with pcDNA3.1 or pcDNA3.1-Ctr1, ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and CCK-8 was used to determine cell viability, ** P <0.01, *** P <0.001 and **** P <0.0001, indicating statistical significance, compared with pcDNA3.1.
    Figure Legend Snippet: The Ctr1 upregulation potentiated the killing efficacy of cisplatin in ESCC cells. A: pcDNA3.1-Ctr1 remarkablely enhanced the Ctr1 mRNA level at 48 h in various ESCC cells (Eca109, Kyse70 and Kyse450), pcDNA3.1 and pcDNA3.1-Ctr1 were transfected to Eca109, Kyse70 and Kyse450 cells by Lipofectamine™ 2000, and Semi-quantitative RT-PCR was used to determine the relative level of Ctr1 at 48 h after transfection,** P <0.01 and *** P <0.001, compared with control group and pcDNA3.1 group. B: Western blot was performed to investigate the Ctr1 protein expression in a number of ESCC cells 48 h after transfection with pcDNA3.1 and pcDNA3.1-Ctr1, and β-actin was used as a loading control. C: The relative level of Ctr1 protein in untreated ESCC cells, ESCC cells transfected with pcDNA3.1 and pcDNA3.1-Ctr1, ** P <0.01, compared with control group and pcDNA3.1 group. D: CCK-8 was used to examine the cell proliferative ability in different concentration of cisplatin with pcDNA3.1 or pcDNA3.1-Ctr1, ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and CCK-8 was used to determine cell viability, ** P <0.01, *** P <0.001 and **** P <0.0001, indicating statistical significance, compared with pcDNA3.1.

    Techniques Used: Transfection, Quantitative RT-PCR, Control, Western Blot, Expressing, CCK-8 Assay, Concentration Assay

    Ctr1 upregulation combined with cisplatin displayed the synergistic role in the induction of cell apoptosis in ESCC cells. A: Flow cytometry assay for cell apoptosis in different ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin, ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Flow cytometry was employed to determine cell apoptosis. B: Statistical assay for apoptotic cell numbers in different ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin, ** P <0.01 and *** P <0.001, compared with pcDNA3.1 plus cisplatin group. C: pcDNA3.1-Ctr1 combined cisplatin significantly promoted the activity of Caspase-3 induced by cisplatin plus pcDNA3.1; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Caspase-3 activity kit was utilized to determine the activity of Caspase-3, ** P <0.01 and *** P <0.001, compared with pcDNA3.1 plus cisplatin group.
    Figure Legend Snippet: Ctr1 upregulation combined with cisplatin displayed the synergistic role in the induction of cell apoptosis in ESCC cells. A: Flow cytometry assay for cell apoptosis in different ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin, ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Flow cytometry was employed to determine cell apoptosis. B: Statistical assay for apoptotic cell numbers in different ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin, ** P <0.01 and *** P <0.001, compared with pcDNA3.1 plus cisplatin group. C: pcDNA3.1-Ctr1 combined cisplatin significantly promoted the activity of Caspase-3 induced by cisplatin plus pcDNA3.1; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Caspase-3 activity kit was utilized to determine the activity of Caspase-3, ** P <0.01 and *** P <0.001, compared with pcDNA3.1 plus cisplatin group.

    Techniques Used: Flow Cytometry, Transfection, Activity Assay

    Ctr1 upregulation exerted the synergistic role in the repression of cell migration and invasion with cisplatin in ESCC cells. A: Transwell assay for cell migration in various ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Transwell chamber without Matrigel was employed to determine cell migration. B: Statistical assay for migratory cell numbers in different ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin, ** P <0.01 and **** P <0.0001, compared with pcDNA3.1 plus cisplatin group. C: Transwell assay for cell invasion in varied ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Transwell chamber with Matrigel was employed to determine cell invasion. D: Statistical assay for invasive cell numbers in a variety of ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin, ** P <0.01 and *** P <0.001, compared with pcDNA3.1 plus cisplatin group.
    Figure Legend Snippet: Ctr1 upregulation exerted the synergistic role in the repression of cell migration and invasion with cisplatin in ESCC cells. A: Transwell assay for cell migration in various ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Transwell chamber without Matrigel was employed to determine cell migration. B: Statistical assay for migratory cell numbers in different ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin, ** P <0.01 and **** P <0.0001, compared with pcDNA3.1 plus cisplatin group. C: Transwell assay for cell invasion in varied ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Transwell chamber with Matrigel was employed to determine cell invasion. D: Statistical assay for invasive cell numbers in a variety of ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin, ** P <0.01 and *** P <0.001, compared with pcDNA3.1 plus cisplatin group.

    Techniques Used: Migration, Transwell Assay, Transfection

    Related Articles

    Control:

    Article Title: Copper transporter Ctr1 contributes to enhancement of the sensitivity of cisplatin in esophageal squamous cell carcinoma
    Article Snippet: ESCC cell lines including Eca109, Kyse70, Kyse450 cells as well as normal esophageal epithelial cell Het-1A were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin (Sigma-Aldrich, USA), and 100 μg/ml streptomycin (Sigma-Aldrich, USA) at 37 °C in an incubator with 5% CO 2 . .. Control siRNA (si-Con) (Santa Cruz company, USA), Ctr1 siRNA (si-Ctr1) (Santa Cruz company, USA), pcDNA3.1 and pcDNA3.1-Ctr1 were transfected to Eca109, Kyse70 and Kyse450 cells by LipofectamineTM 2000 (Invitrogen Life Technologies, Carslbad, CA, USA) according to manufacturer's instruction. .. Total RNA was extracted using Trizol reagent (Invitrogen Life Technologies, Carslbad, CA, USA) according to the manufacturer's protocol. qRT-PCR was performed by Quant one step qRT-PCR Kit (SYBR Green) (TIANGEN BIOTECH CO., LTD, Beijing, China) in an ABI 7500 series PCR machine Applied Biosystems using the following primers: Ctr1F: 5′-AAGATAGCCCGAGAGAGCCT-3′, Ctr1R: 5′-TGGATGATGTG CAGCACTGC-3′ (product size: 176 bp), GAPDHF: 5′-GGGAGCCAAAAGGGT CATCA-3′, GAPDHR: 5′-AGTGATGGCATGGACTGTGG-3′.

    Transfection:

    Article Title: Copper transporter Ctr1 contributes to enhancement of the sensitivity of cisplatin in esophageal squamous cell carcinoma
    Article Snippet: ESCC cell lines including Eca109, Kyse70, Kyse450 cells as well as normal esophageal epithelial cell Het-1A were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin (Sigma-Aldrich, USA), and 100 μg/ml streptomycin (Sigma-Aldrich, USA) at 37 °C in an incubator with 5% CO 2 . .. Control siRNA (si-Con) (Santa Cruz company, USA), Ctr1 siRNA (si-Ctr1) (Santa Cruz company, USA), pcDNA3.1 and pcDNA3.1-Ctr1 were transfected to Eca109, Kyse70 and Kyse450 cells by LipofectamineTM 2000 (Invitrogen Life Technologies, Carslbad, CA, USA) according to manufacturer's instruction. .. Total RNA was extracted using Trizol reagent (Invitrogen Life Technologies, Carslbad, CA, USA) according to the manufacturer's protocol. qRT-PCR was performed by Quant one step qRT-PCR Kit (SYBR Green) (TIANGEN BIOTECH CO., LTD, Beijing, China) in an ABI 7500 series PCR machine Applied Biosystems using the following primers: Ctr1F: 5′-AAGATAGCCCGAGAGAGCCT-3′, Ctr1R: 5′-TGGATGATGTG CAGCACTGC-3′ (product size: 176 bp), GAPDHF: 5′-GGGAGCCAAAAGGGT CATCA-3′, GAPDHR: 5′-AGTGATGGCATGGACTGTGG-3′.



    Similar Products

    ctr1 sirna si ctr1  (Santa Cruz Biotechnology)
    94
    Santa Cruz Biotechnology ctr1 sirna si ctr1
    High expressions of <t>Ctr1</t> mRNA and protein in ESCC tissues and cells. A: Representative image of Ctr1 high expression in ESCC tissues by ISH and IHC; ISH and IHC assay for Ctr1 mRNA and protein expressions in 108 cases of ESCC tissues and paired normal esophageal epithelial tissues, Bar=100 μm. B: Semi-quantitative RT-PCR detection for Ctr1 mRNA expression in randomly selected 10 cases of ESCC tissues and paired normal tissues using Ctr1 specific primers. C: Statistical assay for Ctr1 relative level in ESCC tissues and paired normal tissues, * P <0.05, ** P <0.01, *** P <0.001 and **** P <0.0001, compared para-carcinoma tissues. D: qRT-PCR assay for Ctr1 mRNA expression in ESCC cell lines (Kyse70, Eca109, and Kyse450 cells), ** P <0.01 and *** P <0.001, compared with Het-1A cell. E: Western blot analysis for Ctr1 protein expression in ESCC cell lines (Kyse70, Eca109, and Kyse450 cells), and β-actin was used as loading control. F: Relative Ctr1 protein level in various ESCC cell lines (Kyse70, Eca109, and Kyse450 cells), ** P <0.01, compared with Het-1A cell.
    Ctr1 Sirna Si Ctr1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ctr1+sirna+si+ctr1/CTR1+siRNA/pmc09876974-69-7-10
    Average 94 stars, based on 1 article reviews
    ctr1 sirna si ctr1 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    High expressions of Ctr1 mRNA and protein in ESCC tissues and cells. A: Representative image of Ctr1 high expression in ESCC tissues by ISH and IHC; ISH and IHC assay for Ctr1 mRNA and protein expressions in 108 cases of ESCC tissues and paired normal esophageal epithelial tissues, Bar=100 μm. B: Semi-quantitative RT-PCR detection for Ctr1 mRNA expression in randomly selected 10 cases of ESCC tissues and paired normal tissues using Ctr1 specific primers. C: Statistical assay for Ctr1 relative level in ESCC tissues and paired normal tissues, * P <0.05, ** P <0.01, *** P <0.001 and **** P <0.0001, compared para-carcinoma tissues. D: qRT-PCR assay for Ctr1 mRNA expression in ESCC cell lines (Kyse70, Eca109, and Kyse450 cells), ** P <0.01 and *** P <0.001, compared with Het-1A cell. E: Western blot analysis for Ctr1 protein expression in ESCC cell lines (Kyse70, Eca109, and Kyse450 cells), and β-actin was used as loading control. F: Relative Ctr1 protein level in various ESCC cell lines (Kyse70, Eca109, and Kyse450 cells), ** P <0.01, compared with Het-1A cell.

    Journal: Translational Oncology

    Article Title: Copper transporter Ctr1 contributes to enhancement of the sensitivity of cisplatin in esophageal squamous cell carcinoma

    doi: 10.1016/j.tranon.2023.101626

    Figure Lengend Snippet: High expressions of Ctr1 mRNA and protein in ESCC tissues and cells. A: Representative image of Ctr1 high expression in ESCC tissues by ISH and IHC; ISH and IHC assay for Ctr1 mRNA and protein expressions in 108 cases of ESCC tissues and paired normal esophageal epithelial tissues, Bar=100 μm. B: Semi-quantitative RT-PCR detection for Ctr1 mRNA expression in randomly selected 10 cases of ESCC tissues and paired normal tissues using Ctr1 specific primers. C: Statistical assay for Ctr1 relative level in ESCC tissues and paired normal tissues, * P <0.05, ** P <0.01, *** P <0.001 and **** P <0.0001, compared para-carcinoma tissues. D: qRT-PCR assay for Ctr1 mRNA expression in ESCC cell lines (Kyse70, Eca109, and Kyse450 cells), ** P <0.01 and *** P <0.001, compared with Het-1A cell. E: Western blot analysis for Ctr1 protein expression in ESCC cell lines (Kyse70, Eca109, and Kyse450 cells), and β-actin was used as loading control. F: Relative Ctr1 protein level in various ESCC cell lines (Kyse70, Eca109, and Kyse450 cells), ** P <0.01, compared with Het-1A cell.

    Article Snippet: Control siRNA (si-Con) (Santa Cruz company, USA), Ctr1 siRNA (si-Ctr1) (Santa Cruz company, USA), pcDNA3.1 and pcDNA3.1-Ctr1 were transfected to Eca109, Kyse70 and Kyse450 cells by LipofectamineTM 2000 (Invitrogen Life Technologies, Carslbad, CA, USA) according to manufacturer's instruction.

    Techniques: Expressing, Quantitative RT-PCR, Western Blot, Control

    The expressions of Ctr1 mRNA and protein in ESCC tissues and normal tissues.

    Journal: Translational Oncology

    Article Title: Copper transporter Ctr1 contributes to enhancement of the sensitivity of cisplatin in esophageal squamous cell carcinoma

    doi: 10.1016/j.tranon.2023.101626

    Figure Lengend Snippet: The expressions of Ctr1 mRNA and protein in ESCC tissues and normal tissues.

    Article Snippet: Control siRNA (si-Con) (Santa Cruz company, USA), Ctr1 siRNA (si-Ctr1) (Santa Cruz company, USA), pcDNA3.1 and pcDNA3.1-Ctr1 were transfected to Eca109, Kyse70 and Kyse450 cells by LipofectamineTM 2000 (Invitrogen Life Technologies, Carslbad, CA, USA) according to manufacturer's instruction.

    Techniques:

    The associations of Ctr1 mRNA and protein expressions with clinicopathological features in ESCC.

    Journal: Translational Oncology

    Article Title: Copper transporter Ctr1 contributes to enhancement of the sensitivity of cisplatin in esophageal squamous cell carcinoma

    doi: 10.1016/j.tranon.2023.101626

    Figure Lengend Snippet: The associations of Ctr1 mRNA and protein expressions with clinicopathological features in ESCC.

    Article Snippet: Control siRNA (si-Con) (Santa Cruz company, USA), Ctr1 siRNA (si-Ctr1) (Santa Cruz company, USA), pcDNA3.1 and pcDNA3.1-Ctr1 were transfected to Eca109, Kyse70 and Kyse450 cells by LipofectamineTM 2000 (Invitrogen Life Technologies, Carslbad, CA, USA) according to manufacturer's instruction.

    Techniques:

    The Ctr1 downregulation reduces the sensitivity of cisplatin in ESCC cells. A: Ctr1 siRNA significantly suppressed Ctr1 mRNA expression at 24 h, 48 h and 72 h in various ESCC cells (Eca109, Kyse70 and Kyse450), si-Con and si-Ctr1 were transfected to Eca109, Kyse70 and Kyse450 cells by Lipofectamine™ 2000, and Semi-quantitative RT-PCR was used to determine the relative level of Ctr1 at 24 h, 48 h and 72 h after transfection, ** P <0.01 and *** P <0.001, compared with control group and si-Con group. B: Western blot was performed to investigate the Ctr1 protein expression at 24 h, 48 h and 72 h after transfection with si-Ctr1 and si-Con in different ESCC cells (Eca109, Kyse70 and Kyse450), and β-actin was employed as a loading control. C: The relative level of Ctr1 was counted using the rate of Ctr1 protein level to β-actin level in diverse ESCC cells (Eca109, Kyse70 and Kyse450), * P <0.05, ** P <0.01 and *** P <0.001, compared with control group and si-Con group. D: The Ctr1 downregulation reduced the cytotoxicity of cisplatin in distinct ESCC cells. ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and CCK-8 was used to determine cell viability, * P <0.05, ** P <0.01, *** P <0.001 and **** P <0.0001, indicating statistical significance, compared with si-Con.

    Journal: Translational Oncology

    Article Title: Copper transporter Ctr1 contributes to enhancement of the sensitivity of cisplatin in esophageal squamous cell carcinoma

    doi: 10.1016/j.tranon.2023.101626

    Figure Lengend Snippet: The Ctr1 downregulation reduces the sensitivity of cisplatin in ESCC cells. A: Ctr1 siRNA significantly suppressed Ctr1 mRNA expression at 24 h, 48 h and 72 h in various ESCC cells (Eca109, Kyse70 and Kyse450), si-Con and si-Ctr1 were transfected to Eca109, Kyse70 and Kyse450 cells by Lipofectamine™ 2000, and Semi-quantitative RT-PCR was used to determine the relative level of Ctr1 at 24 h, 48 h and 72 h after transfection, ** P <0.01 and *** P <0.001, compared with control group and si-Con group. B: Western blot was performed to investigate the Ctr1 protein expression at 24 h, 48 h and 72 h after transfection with si-Ctr1 and si-Con in different ESCC cells (Eca109, Kyse70 and Kyse450), and β-actin was employed as a loading control. C: The relative level of Ctr1 was counted using the rate of Ctr1 protein level to β-actin level in diverse ESCC cells (Eca109, Kyse70 and Kyse450), * P <0.05, ** P <0.01 and *** P <0.001, compared with control group and si-Con group. D: The Ctr1 downregulation reduced the cytotoxicity of cisplatin in distinct ESCC cells. ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and CCK-8 was used to determine cell viability, * P <0.05, ** P <0.01, *** P <0.001 and **** P <0.0001, indicating statistical significance, compared with si-Con.

    Article Snippet: Control siRNA (si-Con) (Santa Cruz company, USA), Ctr1 siRNA (si-Ctr1) (Santa Cruz company, USA), pcDNA3.1 and pcDNA3.1-Ctr1 were transfected to Eca109, Kyse70 and Kyse450 cells by LipofectamineTM 2000 (Invitrogen Life Technologies, Carslbad, CA, USA) according to manufacturer's instruction.

    Techniques: Expressing, Transfection, Quantitative RT-PCR, Control, Western Blot, CCK-8 Assay

    Ctr1 depletion prominently repressed cell apoptosis evoked by cisplatin in ESCC cells. A: Flow cytometry assay for cell apoptosis in different ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 as well as si-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Flow cytometry was employed to determine cell apoptosis. B: Statistical assay for apoptotic cell numbers in different ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 as well as si-Ctr1 plus cisplatin, *** P <0.001 and **** P <0.0001, compared with si-Con plus cisplatin group. C: Ctr1 depletion combined cisplatin significantly suppressed the activity of Caspase-3 induced by cisplatin plus si-Con; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Caspase-3 activity kit was utilized to determine the activity of Caspase-3, *** P <0.001, compared with si-Con plus cisplatin group.

    Journal: Translational Oncology

    Article Title: Copper transporter Ctr1 contributes to enhancement of the sensitivity of cisplatin in esophageal squamous cell carcinoma

    doi: 10.1016/j.tranon.2023.101626

    Figure Lengend Snippet: Ctr1 depletion prominently repressed cell apoptosis evoked by cisplatin in ESCC cells. A: Flow cytometry assay for cell apoptosis in different ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 as well as si-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Flow cytometry was employed to determine cell apoptosis. B: Statistical assay for apoptotic cell numbers in different ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 as well as si-Ctr1 plus cisplatin, *** P <0.001 and **** P <0.0001, compared with si-Con plus cisplatin group. C: Ctr1 depletion combined cisplatin significantly suppressed the activity of Caspase-3 induced by cisplatin plus si-Con; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Caspase-3 activity kit was utilized to determine the activity of Caspase-3, *** P <0.001, compared with si-Con plus cisplatin group.

    Article Snippet: Control siRNA (si-Con) (Santa Cruz company, USA), Ctr1 siRNA (si-Ctr1) (Santa Cruz company, USA), pcDNA3.1 and pcDNA3.1-Ctr1 were transfected to Eca109, Kyse70 and Kyse450 cells by LipofectamineTM 2000 (Invitrogen Life Technologies, Carslbad, CA, USA) according to manufacturer's instruction.

    Techniques: Flow Cytometry, Transfection, Activity Assay

    The Ctr1 downregulation meliorated cell migration and invasion abilities inhibited by cisplatin in number of ESCC cells. A: Transwell assay for cell migration in various ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 and si-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Transwell chamber without Matrigel was employed to determine cell migration. B: Statistical assay for migratory cell numbers in different ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 and si-Ctr1 plus cisplatin, *** P <0.001, compared with si-Con plus cisplatin group. C: Transwell assay for cell invasion in varied ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 and si-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Transwell chamber with Matrigel was used to determine cell invasion. D: Statistical assay for invasive cell numbers in a variety of ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 and si-Ctr1 plus cisplatin, *** P <0.001, compared with si-Con plus cisplatin group.

    Journal: Translational Oncology

    Article Title: Copper transporter Ctr1 contributes to enhancement of the sensitivity of cisplatin in esophageal squamous cell carcinoma

    doi: 10.1016/j.tranon.2023.101626

    Figure Lengend Snippet: The Ctr1 downregulation meliorated cell migration and invasion abilities inhibited by cisplatin in number of ESCC cells. A: Transwell assay for cell migration in various ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 and si-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Transwell chamber without Matrigel was employed to determine cell migration. B: Statistical assay for migratory cell numbers in different ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 and si-Ctr1 plus cisplatin, *** P <0.001, compared with si-Con plus cisplatin group. C: Transwell assay for cell invasion in varied ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 and si-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Transwell chamber with Matrigel was used to determine cell invasion. D: Statistical assay for invasive cell numbers in a variety of ESCC cells treated with si-Con, si-Con plus cisplatin, si-Ctr1 and si-Ctr1 plus cisplatin, *** P <0.001, compared with si-Con plus cisplatin group.

    Article Snippet: Control siRNA (si-Con) (Santa Cruz company, USA), Ctr1 siRNA (si-Ctr1) (Santa Cruz company, USA), pcDNA3.1 and pcDNA3.1-Ctr1 were transfected to Eca109, Kyse70 and Kyse450 cells by LipofectamineTM 2000 (Invitrogen Life Technologies, Carslbad, CA, USA) according to manufacturer's instruction.

    Techniques: Migration, Transwell Assay, Transfection

    The Ctr1 upregulation potentiated the killing efficacy of cisplatin in ESCC cells. A: pcDNA3.1-Ctr1 remarkablely enhanced the Ctr1 mRNA level at 48 h in various ESCC cells (Eca109, Kyse70 and Kyse450), pcDNA3.1 and pcDNA3.1-Ctr1 were transfected to Eca109, Kyse70 and Kyse450 cells by Lipofectamine™ 2000, and Semi-quantitative RT-PCR was used to determine the relative level of Ctr1 at 48 h after transfection,** P <0.01 and *** P <0.001, compared with control group and pcDNA3.1 group. B: Western blot was performed to investigate the Ctr1 protein expression in a number of ESCC cells 48 h after transfection with pcDNA3.1 and pcDNA3.1-Ctr1, and β-actin was used as a loading control. C: The relative level of Ctr1 protein in untreated ESCC cells, ESCC cells transfected with pcDNA3.1 and pcDNA3.1-Ctr1, ** P <0.01, compared with control group and pcDNA3.1 group. D: CCK-8 was used to examine the cell proliferative ability in different concentration of cisplatin with pcDNA3.1 or pcDNA3.1-Ctr1, ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and CCK-8 was used to determine cell viability, ** P <0.01, *** P <0.001 and **** P <0.0001, indicating statistical significance, compared with pcDNA3.1.

    Journal: Translational Oncology

    Article Title: Copper transporter Ctr1 contributes to enhancement of the sensitivity of cisplatin in esophageal squamous cell carcinoma

    doi: 10.1016/j.tranon.2023.101626

    Figure Lengend Snippet: The Ctr1 upregulation potentiated the killing efficacy of cisplatin in ESCC cells. A: pcDNA3.1-Ctr1 remarkablely enhanced the Ctr1 mRNA level at 48 h in various ESCC cells (Eca109, Kyse70 and Kyse450), pcDNA3.1 and pcDNA3.1-Ctr1 were transfected to Eca109, Kyse70 and Kyse450 cells by Lipofectamine™ 2000, and Semi-quantitative RT-PCR was used to determine the relative level of Ctr1 at 48 h after transfection,** P <0.01 and *** P <0.001, compared with control group and pcDNA3.1 group. B: Western blot was performed to investigate the Ctr1 protein expression in a number of ESCC cells 48 h after transfection with pcDNA3.1 and pcDNA3.1-Ctr1, and β-actin was used as a loading control. C: The relative level of Ctr1 protein in untreated ESCC cells, ESCC cells transfected with pcDNA3.1 and pcDNA3.1-Ctr1, ** P <0.01, compared with control group and pcDNA3.1 group. D: CCK-8 was used to examine the cell proliferative ability in different concentration of cisplatin with pcDNA3.1 or pcDNA3.1-Ctr1, ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and CCK-8 was used to determine cell viability, ** P <0.01, *** P <0.001 and **** P <0.0001, indicating statistical significance, compared with pcDNA3.1.

    Article Snippet: Control siRNA (si-Con) (Santa Cruz company, USA), Ctr1 siRNA (si-Ctr1) (Santa Cruz company, USA), pcDNA3.1 and pcDNA3.1-Ctr1 were transfected to Eca109, Kyse70 and Kyse450 cells by LipofectamineTM 2000 (Invitrogen Life Technologies, Carslbad, CA, USA) according to manufacturer's instruction.

    Techniques: Transfection, Quantitative RT-PCR, Control, Western Blot, Expressing, CCK-8 Assay, Concentration Assay

    Ctr1 upregulation combined with cisplatin displayed the synergistic role in the induction of cell apoptosis in ESCC cells. A: Flow cytometry assay for cell apoptosis in different ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin, ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Flow cytometry was employed to determine cell apoptosis. B: Statistical assay for apoptotic cell numbers in different ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin, ** P <0.01 and *** P <0.001, compared with pcDNA3.1 plus cisplatin group. C: pcDNA3.1-Ctr1 combined cisplatin significantly promoted the activity of Caspase-3 induced by cisplatin plus pcDNA3.1; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Caspase-3 activity kit was utilized to determine the activity of Caspase-3, ** P <0.01 and *** P <0.001, compared with pcDNA3.1 plus cisplatin group.

    Journal: Translational Oncology

    Article Title: Copper transporter Ctr1 contributes to enhancement of the sensitivity of cisplatin in esophageal squamous cell carcinoma

    doi: 10.1016/j.tranon.2023.101626

    Figure Lengend Snippet: Ctr1 upregulation combined with cisplatin displayed the synergistic role in the induction of cell apoptosis in ESCC cells. A: Flow cytometry assay for cell apoptosis in different ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin, ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Flow cytometry was employed to determine cell apoptosis. B: Statistical assay for apoptotic cell numbers in different ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin, ** P <0.01 and *** P <0.001, compared with pcDNA3.1 plus cisplatin group. C: pcDNA3.1-Ctr1 combined cisplatin significantly promoted the activity of Caspase-3 induced by cisplatin plus pcDNA3.1; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Caspase-3 activity kit was utilized to determine the activity of Caspase-3, ** P <0.01 and *** P <0.001, compared with pcDNA3.1 plus cisplatin group.

    Article Snippet: Control siRNA (si-Con) (Santa Cruz company, USA), Ctr1 siRNA (si-Ctr1) (Santa Cruz company, USA), pcDNA3.1 and pcDNA3.1-Ctr1 were transfected to Eca109, Kyse70 and Kyse450 cells by LipofectamineTM 2000 (Invitrogen Life Technologies, Carslbad, CA, USA) according to manufacturer's instruction.

    Techniques: Flow Cytometry, Transfection, Activity Assay

    Ctr1 upregulation exerted the synergistic role in the repression of cell migration and invasion with cisplatin in ESCC cells. A: Transwell assay for cell migration in various ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Transwell chamber without Matrigel was employed to determine cell migration. B: Statistical assay for migratory cell numbers in different ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin, ** P <0.01 and **** P <0.0001, compared with pcDNA3.1 plus cisplatin group. C: Transwell assay for cell invasion in varied ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Transwell chamber with Matrigel was employed to determine cell invasion. D: Statistical assay for invasive cell numbers in a variety of ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin, ** P <0.01 and *** P <0.001, compared with pcDNA3.1 plus cisplatin group.

    Journal: Translational Oncology

    Article Title: Copper transporter Ctr1 contributes to enhancement of the sensitivity of cisplatin in esophageal squamous cell carcinoma

    doi: 10.1016/j.tranon.2023.101626

    Figure Lengend Snippet: Ctr1 upregulation exerted the synergistic role in the repression of cell migration and invasion with cisplatin in ESCC cells. A: Transwell assay for cell migration in various ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Transwell chamber without Matrigel was employed to determine cell migration. B: Statistical assay for migratory cell numbers in different ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin, ** P <0.01 and **** P <0.0001, compared with pcDNA3.1 plus cisplatin group. C: Transwell assay for cell invasion in varied ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin; ESCC cells (Eca109, Kyse70 and Kyse450) were harvested at 48 h after transfection, different doses of cisplatin was applied to ESCC cells above, and Transwell chamber with Matrigel was employed to determine cell invasion. D: Statistical assay for invasive cell numbers in a variety of ESCC cells treated with pcDNA3.1, pcDNA3.1 plus cisplatin, pcDNA3.1-Ctr1 and pcDNA3.1-Ctr1 plus cisplatin, ** P <0.01 and *** P <0.001, compared with pcDNA3.1 plus cisplatin group.

    Article Snippet: Control siRNA (si-Con) (Santa Cruz company, USA), Ctr1 siRNA (si-Ctr1) (Santa Cruz company, USA), pcDNA3.1 and pcDNA3.1-Ctr1 were transfected to Eca109, Kyse70 and Kyse450 cells by LipofectamineTM 2000 (Invitrogen Life Technologies, Carslbad, CA, USA) according to manufacturer's instruction.

    Techniques: Migration, Transwell Assay, Transfection